Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBenedito Mauro Rossi
About this trial
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
Eligibility criteria
Qualifiers
Patients diagnosed with metastatic PDAC;
Patients who will start treatment with FOLFIRINOX;
18 years or older;
Who agree to participate in the study by signing the Informed Consent Form;
Disqualifiers
Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsSponsors and collaborators
Benedito Mauro Rossi
Lead sponsor
Beneficência Portuguesa de São Paulo
Sponsor institution
Source ClinicalTrials.gov